Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Radius Heal is a drug manufacturers-specialty & generic business based in the US. Radius Heal shares (RDUS) are listed on the NASDAQ and all prices are listed in US Dollars. Radius Heal employs 293 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $10.48 |
|---|---|
| 52-week range | $4.97 - $23.00 |
| 50-day moving average | $7.17 |
| 200-day moving average | $10.11 |
| Wall St. target price | $9.60 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.54 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.48 from 2022-07-01
| 1 week (2022-06-28) | -0.19% |
|---|---|
| 1 month (2022-06-01) | N/A |
| 3 months (2022-04-05) | 20.18% |
| 6 months (2022-01-05) | 67.41% |
| 1 year (2021-07-02) | -41.29% |
|---|---|
| 2 years (2020-07-02) | -26.04% |
| 3 years (2019-07-05) | 24.62 |
| 5 years (2017-07-03) | 45.95 |
| Revenue TTM | $216.9 million |
|---|---|
| Gross profit TTM | $211.6 million |
| Return on assets TTM | -17.8% |
| Return on equity TTM | 0% |
| Profit margin | -33.52% |
| Book value | $0.00 |
| Market capitalisation | $493.6 million |
TTM: trailing 12 months
We're not expecting Radius Heal to pay a dividend over the next 12 months.
Radius Heal's shares were split on a 25:57 basis on 23 April 2014. So if you had owned 57 shares the day before before the split, the next day you'd have owned 25 shares. This wouldn't directly have changed the overall worth of your Radius Heal shares – just the quantity. However, indirectly, the new 128% higher share price could have impacted the market appetite for Radius Heal shares which in turn could have impacted Radius Heal's share price.
Over the last 12 months, Radius Heal's shares have ranged in value from as little as $4.97 up to $23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Radius Heal's is 1.0336. This would suggest that Radius Heal's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Radius Health, Inc. , a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd. ; and Duke University.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.